Daniel D. Han, MS

Excited to have our work highlighted! @VKutyifa

New #URochesterResearch uncovers a new biomarker of heart cells that surround the dead tissue left by a heart attack. @Eric66867284 & his team developed a new mouse model to study these cells & their role in heart repair & regeneration. More in @CircAHA: ahajournals.org/doi/10.1161/CI…

Late-breaker presentation is Tuesday 11:00 am on novel GDMT in #BIOLIBRA don’t miss it #EHRA2026 @ESCardioNews

Sprr1a acts a novel marker for specific subpopulation of border zone cardiomyocytes in mice, that survive myocardial infarction, facilitating their direct visualization, isolation, and longitudinal tracking. ahajrnls.org/3OmYZUW

You can read more here: link.springer.com/article/10.100…

Excited to share that my first, first-author case report is published in the International Journal of Cardiothoracic Imaging. We looked at a case of Desmoplakin cardiomyopathy with clear ring-like lesion in Late-Gadolinium Enhancement. Thank you @JoslinKapr34515 for your support!

You can read more here: academic.oup.com/eschf/advance-…

My first, first-author clinical paper is out @ESCHeartFailure Non-Obese patients with Metabolic Syndrome has similar high HF risks as obese. Having Diabetes further raised the risk! Our work calls for more focus for managing these patients! Thank you @VKutyifa for your mentorship

Honored to organize the symposium with @SominskyLevy Please register and submit your abstracts if you have any interesting data!! Also, please come out to hear our keynote presentation from Dr. Rajan Jain #Cardiology #nucleus

VEXAS syndrome is a newly discovered multisystemic disease affecting most organs. A Review provides a comprehensive overview of VEXAS syndrome, including the disease's discovery, diagnosis, and treatment: spkl.io/6011AQPUJ

It was a wonderful opportunity to discuss about potential sex differences in heart failure outcomes in patients with metabolic syndrome and implantable cardiac devices #MADIT @RocMSTP @UR_Med @URochester_SMD

Our brilliant MSTP student, Daniel Han presenting on sex-differences in metabolic syndrome at the Research in Health Equity Symposium @URMC_DeptMed @DanielDWHan

@VKutyifa @URMC_DeptMed Thank you so much for your mentorship!!

Several impactful papers influencing the treatment of patients with #HeartFailure have been published in 2025 @ESC_Journals #EHJ academic.oup.com/eurheartj/adva…

On #KoreanAmericanDay, we honor the leadership, service and culture Korean Americans have contributed and continue to contribute to San Francisco and our country. The Korean American community is an enduring part of our nation’s story—and America is all the stronger for it.

Trial almost complete!! Our NIH-funded HIS-CRT trial enrolled 115 of 120 participants, enrolling females now. We need evidence on the efficacy of HIS-CRT to accurately treat female patients. Our fantastic patient representative, Rhonda Monroe shared insights on "HIS-CRT for HER". @DrRoderickTung @kennethellenbogen @NIH #EPPEEPS #ClinicalTrials clinicaltrials.gov/study/NCT05265…

Great Interview Leila!!!

In the SARAH trial, sacubitril-valsartan reduced LV dysfunction in patients with anthracylcine related cardiotoxicity @Bocchi @MBittencourtMD @monicaAGrinberg @lukadalech @larimosko ahajrnls.org/3LOgpZ5

Real-world evidence shows semaglutide and tirzepatide deliver similar reductions in major CV events for people with obesity & type 2 diabetes. nature.com/articles/s4159…